




DOI 10.1016/j.chembiol.2009.09.008Existing drugs can be roughly classified
either as biologics or small molecules.
Biologics include antibodies or insulin
that does not penetrate into cells, which
limits their target range, as <10% of
human proteins are found on cell
surfaces or are secreted. Although able
to penetrate cells, small molecules have
limitations of their own. ‘‘The entire
biotech industry has been working on
10% of human targets,’’ said Gregory
Verdine, Ph.D., Erving professor of
chemistry, Harvard University. ‘‘Small
molecules only work on proteins that
have a specific feature on their surfaces.
That is another 10% of all human targets.
So that means 80% are not approach-
able by the two established modes of
drugs.’’910 Chemistry & Biology 16, September 25,energy-dependent active transport and
usually have a higher affinity to large
protein surfaces.
The company believes its stapled
a-helical peptides have wide therapeutic
potential for cancer, autoimmune, inflam-
matory, infectious, and metabolic dis-
eases. Aileron was started in 2005 by
CEOJosephYanchik, III, using IP licensed
from Verdine at Harvard and cofounders
Loren Walensky, M.D., Ph.D., assistant
professor of pediatrics, and the late
StanleyJ.Korsmeyer,M.D., SidneyFarber
professor of pathology and professor of
medicine, at the Dana-Farber Cancer
Institute and Harvard Medical School.
Aileron Therapeutics is funded by
the investment arms of four pharma-
ceutical companies. In June 2009, it[Aileron Therapeutics] is going after what were previously consid-
ered undruggable targetsWielding the Chemical Staple Gun
Verdine and Cambridge, MA, based Aile-
ron Therapeutics (http://www.aileronrx.
com) believe that they have found the
key to accessing this so-far untapped
universe of targets. Proteins, through their
subdomains, play a role in almost every
cellular process in the body; however,
subdomain-derived peptides have been
difficult to turn into drugs. Because they
lack defined structure, these peptides
are quickly degraded by proteases and
are dispatched by the kidneys. Currently,
there are more than 40 peptide drugs on
the market, such as Amylin’s Byetta, an
a-helical peptide treatment for diabetes,
but the drugs target receptors on the
cells’ surfaces.
Aileron Therapeutics stabilizes pep-
tides by ‘‘stapling’’ them with hydro-
carbon bonds into an a helix, a structure
peptides can naturally assume in pro-
teins. Thus constrained in a helical forma-
tion, the peptides are protected from the
depredations of proteases. The stabilized
a-helical peptides can penetrate cells byannounced a $40 million D funding
round from Apple Tree Partners, SROne,
Ltd. (GlaxoSmithKline), Excel Medical
Fund, Novartis Venture Fund, Lilly
Ventures, and Roche Venture Fund.
Breaking Down Barriers
for a-Helical Peptides
Chemically constraining peptides into
a helix has challenged researchers for
decades. Verdine’s lab applied the cata-
lyst developed by Nobel laureate Robert
Grubbs, Ph.D. at CalTech. ‘‘We knew
that a helices were frequently involved in
mediating protein-protein interactions,’’
Verdine said. ‘‘We also knew by maxi-
mizing helix stability we would solve the
problem of proteolytic degradation. No
protease can recognize an a helix.’’ But,
according to Verdine, stabilized a-helix
peptides previously developed by other
research labs did not penetrate cells.
To stabilize peptides, Verdine and his
postdoc Christian Schafmeister, Ph.D.
(now associate professor, Department of
Chemistry, Temple University) used an2009 ª2009 Elsevier Ltd All rights reservedolefin metathesis reaction. They drew
upon the work of Isabella Karle, Ph.D,
the former chief scientist at the Office of
Naval Research, X-Ray Diffraction Sec-
tion, who showed that adding a methyl
groups to the peptides could locally stabi-
lize the rings of the helix, and of Peter
Schultz, Ph.D, professor of chemistry,
Scripps Research Institute, who showed
that macrocycle rings connecting adja-
cent turns of the helix created a global
stabilizing effect. Staple placement also
mattered.
Proteins can’t penetrate a cell wall
because they have too many polar atoms
and are generally hydrophilic, thus, they
are incompatible with the hydrophobic
interior of the membrane. This led to the
idea that the macrocycle ring should be
all hydrocarbon. ‘‘We didn’t want any
atoms to impede cell penetration,’’ said
Verdine. Loren Walensky, then a postdoc
in Verdine’s lab, discovered that the stabi-
lized cell helices didn’t penetrate the cell
via passive diffusion, but by active endo-
somal uptake. ‘‘That was a serendipitous
but very, very important discovery,’’ said
Verdine. ‘‘What is so great about it is
that it has broad applicability to a wide
variety of peptides.’’
According to Verdine, bioavailability
was another hurdle. For instance, when
antisense oligonucleotides are taken up
into the cell by endosomal trafficking,
they can’t get out of the endosome; how-
ever, stapled helixes are excellent escape
artists. For example, the cell’s nuclear
envelop blocks passage of anything over
25 kDa, but allows smaller molecules
through. Stapled a-helical peptides are
small enough to access targets in the
nucleus and in the cytoplasm. The syn-
thetic peptides have a similar binding
specificity to the protein from which they
were derived.
Playing Cell Guardians
and Executioners Off Each Other
Loren Walensky’s laboratory is develop-
ing new strategies to study and treat
Chemistry & Biology
Innovationschildhood malignancies, focusing in par-
ticular on recurring cancers that are
unresponsive to existing treatments. Wa-
lensky researched a-helical stapled pep-
tides to investigate and modulate cell
death pathways as a postdoctoral fellow
in the laboratories of Verdine and Stanley
Korsmeyer, who was a pioneer in ap-
optosis research.
The Bcl-2 family of proteins regulates
apoptosis, interacting in Byzantine fash-
ion to dictate the life and death of cells.
In a cancerous cell, the balance among
Bcl-2 proteins goes haywire, blocking
signals that initiate cell suicide. ‘‘A key
interaction element for this family is the
conserved BH3 death helix,’’ said Walen-
sky. ‘‘There are two basic classes of re-
gulators: survival proteins and death
proteins. Our goal is to use this natural
helical motif to block survival proteins,
shutting down their protective force field,
and directly activate the death proteins.’’
Cancer cells may be more susceptible
to pharmacologic death triggers, accord-
ing to Walensky, because their survival
proteins, while successful at maintaining
cancer cell immortality, are barraged
with internal and external stress signals.
His current working hypothesis is that tar-
geting the overtaxed survival pathways of
cancer cells would be enough to tip them
over the edge, while sparing normal cells.
In a 2004 Science paper, Walensky,
Verdine, and Korsmeyer used stapled
BH3 a-helical peptides to induce apo-
ptosis of cancer cells, reducing the prolif-
eration of transplanted cancer in mice
(Walensky et al., 2004). In a 2008 Nature
paper, Walensky and colleagues discov-
ered how the BH3 helix of the pro-
apoptotic Bcl-2 protein BIM directly binds
and activates the BAX protein to trigger
apoptosis (Gavathiotis et al., 2008). ‘‘The
Bcl-2 family interaction network is as
fascinating as it is complex,’’ Walensky
said. ‘‘Deploying stapled peptides as
molecular probes and prototype thera-
peutics is leading us to new biology and
hopefully new drugs to treat disease.’’
Collaborating with Walensky, Nika
Danial, Ph.D., assistant professor of pa-
thology at Harvard, discovered that the
proapoptotic Bcl-2 protein BAD toggles
between regulating apoptosis and me-
tabolism by turning its death helix on
and off. ‘‘Findings like this teach us to
stay open-minded, since Bcl-2 proteins
may have unanticipated functions out-side the apoptotic pathway,’’ Walensky
said.
At the 2008 American Association for
Clinical Cancer Research (AACR) annual
meeting, Aileron debuted a study showing
that stapled a-helical peptides based on
the BH3 domains of proapoptotic BID
and BIM proteins dose-responsively sup-
pressed cell growth of various cancers
in vitro and in mice. Owing to their struc-
tural stability, the peptides survived in
the body for several hours.
A Tale of Two Molecules
Abbott Laboratories’ ABT-263 is a rival
compound to regulate apoptosis for
cancer treatment. ABT-263 is currently
in phase I/II clinical trials run by Genen-
tech and Abbott for various cancer indica-
tions.
In 1996, Stephen Fesik, Ph.D, and his
team at Abbott Laboratories determined
the 3D structures of proteins involved in
apoptosis, including the structure of a
Bcl-2 family protein, Bcl-XL. According
to Fesik, while apoptosis is triggered in
damaged cells, in some cancer cells the
apoptosis signal becomes deregulated
and the cell doesn’t die. The team pub-
lished papers in 1996 (Muchmore et al.,
1996) and 1997 (Sattler et al., 1997)
describing how the antiapoptotic protein
Bcl-xL interacted with a peptide derived
from BAK, a proapoptotic member of the
same family. ‘‘We were able to define
what were the hotspots and important
interactions that stabilized complex
formation,’’ Fesik said. ‘‘We thought we
could come up with a small molecule
that could essentially mimic the BAK
peptide.’’
Fesik’s team used NMR to identify
fragments of the ultimate molecule they
wanted to make and painstakingly con-
structed it. The resulting molecule, ABT
737, which was published in Nature in
2005, required IV administration. The
team used medicinal chemistry to de-
velop an orally active analog called ABT
263 (Oltersdorf et al., 2005).
‘‘ABT-263 potently inhibits Bcl-xL,
Bcl-w, and Bcl-2,’’ said Fesik. ‘‘In addi-
tion, ABT 263 regresses tumors in animal
models and is showing promising anti-
cancer activity in early stage clinical trials.
However, ABT 263 does not inhibit Mcl-1.
In certain cancers, Mcl-1 drives the antia-
poptotic response, so for patients with
high levels of Mcl-1, ABT 263 wouldChemistry & Biology 16, September 25, 200have to be delivered in combination with
other drugs.’’
According to Fesik, while developing
a drug using stapled a helices is poten-
tially easier, as the a-helical form already
occurs in nature and just needs to be
modified, Aileron now has to further prove
the methodology. ‘‘They have to demon-
strate the promise of this technology in
clinical trials,’’ said Fesik.
Fesik’s accomplishment was a ‘‘tour de
force in making a small molecule,’’ said
Tomi Sawyer, Ph.D., chief scientific
officer at Aileron Therapeutics. ‘‘It was
elegant and leveraged a fragment-based
approach to small molecule lead genera-
tion and optimization.’’ According to Saw-
yer, ABT-253 is designed for a specific
target, while a-helical stapled peptides
can be redesigned to achieve desired
specificities for various targets. Aileron is
developing a series of stapled peptides
particularly effective against Mcl-1.
According to Sawyer, stapled peptides
have target selectivity based on natural
helical protein-protein interactions that is
not readily achieved by small molecules.
Cell penetration mechanisms for stapled
peptides involve active transport pro-
cesses, compared to small molecules
which mainly penetrate into cells by
passive diffusion. ‘‘Our first challenge
was to get past the in vitro testing to
understand if there are any limitations of
stapled peptides’ PK properties,’’ said
Sawyer. So far, Aileron has optimized
the half-lives of key stapled peptides to
24 hr and is evaluating candidates
in vitro and in vivo.
‘‘It is an innovative modality with sup-
porting data, albeit early stage,’’ said
Michael Diem, M.D., partner at SROne.
According to Diem, while the Abbott
molecule is the most advanced so far in
the Bcl-2 pathway, what makes Aileron
Therapeutics interesting to the pharmas
is its breadth of platform. ‘‘It is going after
what were previously considered undrug-
gable targets,’’ Diem said.
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